Back to journals
Academic Journal

Journal of Psychopharmacology

194 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat

This observational study (n=29) examined daily voice journals before and after a 5-MeO-DMT retreat and found that speech changed towards more cognitive and less social language, with altered voice quality. Baseline speech patterns also helped predict preparedness, emotional breakthrough and later well-being.

Published
Journal
Journal of Psychopharmacology
Authors
Kuc, J., McAlpine, R. G., Sellers, A., Blackburne, G., Lametti, D. R., Skipper, J. I.
Paywallindividual

5-HT1A receptor blockade potentiates the subjective effects of DMT

This double-blind, randomised, placebo-controlled within-subjects study (n=12) found that blocking the 5-HT1A receptor with 30 mg oral pindolol before a sub-hallucinogenic intravenous dose of DMT (7 mg/70kg) intensified the subjective effects with a moderate effect size, suggesting the 5-HT1A receptor contributes to how psychedelics produce their subjective effects.

Published
Journal
Journal of Psychopharmacology
Authors
Zahid, Z., Strassman, R. J., Qualls, C. R., Nayak, S. M.
Open Accessindividual

Effects of psychedelic use on authoritarian attitudes revisited

This re-analysis of three studies found no clear change in authoritarian attitudes after psychedelic use, including in people who planned to take psychedelics, healthy volunteers given psilocybin, and patients with depression in a randomised trial.

Published
Journal
Journal of Psychopharmacology
Authors
Simonsson, O., Lyons, T., Marks, J., Kettner, H., Roseman, L., Haijen, E., Kaelen, M., Carhart-Harris, R.
Paywallindividual

Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression

This open-label Phase 2 trial (n=14) found that adults with treatment-resistant depression who received intranasal esketamine had improving depression scores over time, and that higher baseline interleukin-6 was linked to faster symptom reduction. Lower interleukin-6 was associated with worse depression and greater disability, while interleukin-6 levels themselves did not change during treatment.

Published
Journal
Journal of Psychopharmacology
Authors
Colizzi, M., Morandin, E., Croccia, V., Scipioni, C., Rosada, C., Sepulcri, O., Balestrieri, M., Garzitto, M.
Open Accessmeta

Trip killers: Addressing a critical knowledge gap in psychedelic research

This review (2026) examines medicines that might be used to stop or reduce severe distress during a psychedelic “bad trip”, focusing on serotonin antagonists, antipsychotics, and some anxiety and depression drugs. It also considers how these drugs work, how quickly they act, their safety, and how they might be used in emergency care.

Published
Journal
Journal of Psychopharmacology
Authors
O’Mahony, B., Harrington, C., Harkin, A., Lally, N.
Open Accessmeta

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics

This review (2026) highlights Roland Griffiths’ major contributions to behavioural and neuropsychopharmacology, particularly his methodical work on abuse liability assessment for alcohol, nicotine, caffeine, and benzodiazepines, alongside his later pioneering research on psychedelics. It also emphasises that his collaborative, mentoring style was central to the development of influential research programmes, including the Johns Hopkins Centre for Psychedelic and Consciousness Research.

Published
Journal
Journal of Psychopharmacology
Authors
Henningfield, J. E., Barrett, F. S., Evans, S. M., Garcia-Romeu, A., Garrett, B. E., Hienz, R. D., Lukas, S. E., Nayak, S. M., Strain, E. C., Weerts, E. M., Yaden, M. E., Yaden, D. B.

Quick Facts

Papers Indexed
194
h-Index
143
Open Access
No
Publisher
SAGE Publications
Country
United Kingdom
Website
Visit